Latest Healthcare News

Beam Dental Bidco Pty Ltd has launched an unconditional $2.20 per share takeover bid for Pacific Smiles Group Limited, offering a 37.5% premium and aiming to consolidate full ownership. The offer is unanimously recommended by Pacific Smiles’ Independent Board Committee, with plans to delist the company from the ASX upon success.

Pacific Smiles Group has agreed to an unconditional $2.20 per share cash takeover offer from its majority shareholder Genesis Bidco, representing a 37.5% premium. The Independent Board Committee recommends shareholders accept the offer, pending no superior proposal and ongoing fairness confirmation.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Immutep Limited has enrolled over 170 patients in its global Phase III TACTI-004 trial for advanced non-small cell lung cancer, surpassing the threshold needed for a futility analysis expected in early 2026.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Pro Medicus Limited’s European arm, Visage Imaging, has landed a significant five-year, A$10 million contract to supply next-generation imaging technology to University Hospital Heidelberg and the German Cancer Research Institute, marking a strategic expansion in Europe.

Adamantem Capital Management has completed its due diligence on Apiam Animal Health and extended its exclusivity period to negotiate a potential $0.87 per share acquisition. The deal remains subject to approvals and binding agreements.

Cyclopharm Ltd has been hit with legal proceedings by 4D Medical Limited, accusing it of making false and misleading statements during a March webinar. Cyclopharm denies the allegations, calling the claim without merit.

ECS Botanics reports a positive cash flow milestone in Q1 FY26, driven by strong direct-to-consumer sales and operational efficiencies, while preparing for a European market debut.